Navigation Links
Boca Pharmacal Receives FDA Approval for Carbinoxamine Maleate 4 mg Tablet
Date:6/2/2008

CORAL SPRINGS, Fla., June 2 /PRNewswire/ -- Boca Pharmacal, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Pamlab's Palgic(R) 4mg Tablet (Carbinoxamine Maleate 4 mg Tablet). The Company plans to launch its product immediately.

Carbinoxamine Maleate 4mg Tablet is indicated to treat seasonal and perennial allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and food, mild, uncomplicated allergic skin manifestations of urticaria and angioedema, dermatographism, as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after acute manifestations have been controlled and amelioration of the severity of allergic reactions to blood or plasma.

"In a world of rising healthcare costs we pride ourselves on our ability to offer lower volume items that may have been overlooked by the generic pharma giants," commented Robert J. Edwards Jr., CEO. "This is another example of our continuing effort to provide affordable prescription drugs. Carbinoxamine Maleate 4mg Tablet is one more approval stemming from strong R&D and a robust product pipeline. We are pleased with our success and look forward to more filings and approvals this year."

Founded in 1998 Coral Springs, FL based Boca Pharmacal is an emerging specialty pharmaceutical company that develops, manufactures, markets, and distributes generic pharmaceutical products.


'/>"/>
SOURCE Boca Pharmacal, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mission Pharmacal Launches Ferralet(R) 90 for Treatment of the Leading Cause of Anemia in the U.S.
2. Boca Pharmacal Receives FDA Approval for Carbinoxamine Oral Solution
3. Mission Pharmacal Launches CitraNatal(TM) Prescription Prenatal Vitamin Line
4. Mission Pharmacal Congratulates Exemplary Womens Health Researchers
5. PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL
6. Edwards Lifesciences Receives Additional Questions From the FDA About the LifeStent Product Line
7. Lupin Receives USFDA Approval for Topiramate Tablets
8. Ohio State receives $34M NIH grant
9. IPRO Receives Google Advertising Grant
10. Harvard Medical School receives major NIH grant for galvanizing translational science
11. BUMC, BMC receives Clinical and Translational Science Award from NIH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/19/2017)... venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound ... ... Jim Bertolina, PhD ... Tom Tefft ... device executive Josh Stopek , PhD, who has led R&D and business development teams ...
Breaking Medicine Technology: